{
    "clinical_study": {
        "@rank": "132862", 
        "arm_group": [
            {
                "arm_group_label": "Sustained-Release Desvenlafaxine Hydrochloride", 
                "arm_group_type": "Experimental", 
                "description": "50-100mg/d"
            }, 
            {
                "arm_group_label": "Sustained-Release Venlafaxine Hydrochloride", 
                "arm_group_type": "Active Comparator", 
                "description": "75-225mg/d"
            }
        ], 
        "brief_summary": {
            "textblock": "A multicenter, 10-week study to evaluate the efficacy and safety of Sustained-Release\n      Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride in adult\n      with major depressive disorder."
        }, 
        "brief_title": "A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult with primary diagnosis of Major Depressive Disorder\n\n          -  Aged from 18 years to 65 years\n\n          -  A primary diagnosis of Major Depressive Disorder based on the criteria in the\n             Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM- IV-TR),\n             single or recurrent episode, without psychotic features\n\n          -  Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \u2267 20\n\n          -  Clinical Global Impressions Scale-Severity (CGI-S) score of \u22674\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to desvenlafaxine or venlafaxine\n\n          -  Significant risk of suicide based on clinical judgment\n\n          -  Women who were pregnant,breast-feeding,or planning to become pregnant during study\n\n          -  Had a history of seizure disorder\n\n          -  History or current evidence of gastrointestinal disease known to interfere with the\n             absorption or excretion of drugs or a history of surgery known to interfere with the\n             absorption or excretion of drugs\n\n          -  Any unstable hepatic, renal, pulmonary, cardiovascular, ophthalmologic, neurologic,\n             or other severe acute or chronic medical or psychiatric condition or laboratory\n             abnormality that may increase the risk associated with study participation or\n             investigational product administration or may interfere with the interpretation of\n             study results\n\n          -  Cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977378", 
            "org_study_id": "DVS20130806"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sustained-Release Desvenlafaxine Hydrochloride", 
                "intervention_name": "Sustained-Release Desvenlafaxine Hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sustained-Release Venlafaxine Hydrochloride", 
                "intervention_name": "Sustained-Release Venlafaxine Hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Venlafaxine", 
                "O-desmethylvenlafaxine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Guangdong General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan"
                    }, 
                    "name": "The Second Xiangya Hospital of Central South University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan"
                    }, 
                    "name": "West China Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100096"
                    }, 
                    "name": "Beijing HuiLongGuan Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100088"
                    }, 
                    "name": "Beijing An Ding Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lhlh_5@163.com", 
                    "last_name": "Huafang Li, Professor", 
                    "phone": "86-021-34773128"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200030"
                    }, 
                    "name": "The Shanghai Mental Health"
                }, 
                "investigator": {
                    "last_name": "Huafang Li, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder", 
        "overall_contact": {
            "email": "lhlh_5@163.com", 
            "last_name": "Huafang Li, Professor", 
            "phone": "86-021-34773128"
        }, 
        "overall_official": {
            "affiliation": "The Shanghai Mental Health", 
            "last_name": "Huafang Li, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 10"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977378"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline on the Clinical Global Impression Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }, 
            {
                "measure": "Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }, 
            {
                "measure": "Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 10", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }, 
            {
                "measure": "Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }, 
            {
                "measure": "Change From Baseline on the Visual Analogue Scale-Pain Intensity (VAS-PI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }, 
            {
                "description": "Remission was defined as a HAM-D17 score of less than or equal to 7.", 
                "measure": "Number of Participants in Remission Based on the HAM-D17 at Week 10", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 10"
            }
        ], 
        "source": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}